ERBB2 and breast carcinoma: Korkaya et al.22 generated trastuzumab resistant HER2+ breast cancer cells by knocking down PTEN, and found that this resistance to trastuzumab was mediated by an IL-6 inflammatory feedback loop, resulting in increased levels of intracellular IL-6 and expansion of a cancer stem cell population.